La Jolla Pharmaceutical Co. (LJPC)
-OTC BB 0.08 0.00(0.00%) May 17, 2:24PM EDT
| Prev Close: | 0.08 |
|---|
| Open: | 0.08 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.30 |
|---|
| Beta: | 0.47 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.08 - 0.08 |
|---|
| 52wk Range: | 0.04 - 0.14 |
|---|
| Volume: | 33,820 |
|---|
| Avg Vol (3m): | 210,324 |
|---|
| Market Cap: | 2.44M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.28 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- LA JOLLA PHARMACEUTICAL CO FinancialsEDGAR Online Financials(Fri, May 17)
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Wed, May 15)
- La Jolla Pharmaceutical Company Presents Corporate Update at the MoneyShowMarketwired(Tue, May 14)
- La Jolla Pharmaceutical Company Announces First-Quarter 2013 Financial Results and Highlights Recent Corporate ProgressMarketwired(Mon, May 13)
- LA JOLLA PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 13)
- La Jolla Pharmaceutical Company Announces Completion of Phase 1 Portion of GCS-100 Clinical Trial in Chronic Kidney DiseaseMarketwired(Mon, May 6)
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other EventsEDGAR Online(Sun, Apr 28)
- La Jolla Pharmaceutical Company Receives Orphan Designation From FDA for LJPC-6417Marketwired(Thu, Apr 18)
- Abbott: Galectin-3 Assay Sees Approval And Builds Takeover Case For La Jolla Pharmaceuticalsat Seeking Alpha(Mon, Apr 15)
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, Apr 4)
- La Jolla Pharmaceutical Announces Start of Common Stock Quotation on OTCBBMarketwired(Wed, Apr 3)
- La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2012 Financial Results and Highlights Recent Corporate ProgressMarketwired(Mon, Apr 1)
- LA JOLLA PHARMACEUTICAL CO Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- Biotech Stocks With Recent Developments: 3 To Consider, 1 To Avoidat Seeking Alpha(Wed, Mar 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-08)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-08)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the development of therapies to treat human diseases that comprise cancer and chronic organ failure.
View More